Genes & Cancer | Reaching beyond family history as inclusion criteria for pancreatic cancer surveillance in high-risk populations
Genes & Cancer, News
September 30, 2022PRESS RELEASE: A new editorial paper was published in Genes & Cancer on August 29, 2022, entitled, “Reaching beyond family history as inclusion criteria for pancreatic cancer surveillance in high-risk populations.”
BUFFALO, NY- September 30, 2022 – A new editorial paper was published in Genes & Cancer on August 29, 2022, entitled, “Reaching beyond family history as inclusion criteria for pancreatic cancer surveillance in high-risk populations.”
Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second most deadly cancer in the United States by 2030. Although stage 1A PDAC 5-year survival is now greater than 80%, the majority of PDAC is diagnosed at more advanced stages, with 5-year survival being less than 10% for stage III/IV disease. The majority of PDAC is sporadic, however up to 10% of PDAC is considered to be familial [3], including individuals with a pathogenic or likely pathogenic variant (PV) in a known PDAC susceptibility gene and/or familial pancreatic cancer, defined as a family with at least two relatives with PDAC who are directly related to one another without known genetic susceptibility.
The researchers who wrote this editorial, Louise Wang, Susan M. Domchek, Michael L. Kochman, and Bryson W. Katona from the University of Pennsylvania Perelman School of Medicine, also wrote:
“As surgical resection of early-stage disease offers the highest chance of long-term survival, effective pancreatic cancer surveillance in high-risk individuals (HRIs) is imperative to allow for early detection.”
At the end of their editorial, the researchers noted that, while some reports have not shown strong evidence that pancreatic cancer surveillance is effective, older as well as more recent data from the Cancer of the Pancreas Screening (CAPS) studies showed that only 5% of surveillance detected PDACs in HRIs were stage IV, while 86% of PDACs diagnosed outside of surveillance were stage IV.
“The data supporting PDAC surveillance in HRIs is encouraging, however there remain fundamental uncertainties in the field which will only be resolved by continued close follow-up of HRIs undergoing PDAC surveillance and capturing of this critically important data in clinical studies.”
DOI: https://doi.org/10.18632/genesandcancer.223 (PDF download file)
Correspondence to: Bryson W. Katona – Email: bryson.katona@pennmedicine.upenn.edu
Keywords: pancreatic cancer surveillance, pancreatic cancer risk, endoscopic ultrasound, MRI
VISIT GENES & CANCER YOUTUBE CHANNEL FOR MORE VIDEOS
—
About Genes & Cancer:
Genes & Cancer covers all aspects of the structure and function of oncogenes, growth suppressor and apoptotic genes, their role in signal transduction and the mechanisms by which their expression and function are altered during tumor development. In addition to publishing manuscripts that directly relate to these areas of research, Genes & Cancer also aims to attract papers in the areas of genomics, drug development and systems biology.
To learn more about Genes & Cancer, visit www.genesandcancer.com and connect with us on social media:
For media inquiries, please contact: media@impactjournals.com.
